Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
55.13
-2.24 (-3.90%)
Nov 15, 2024, 4:00 PM EST - Market closed
Revolution Medicines Employees
Revolution Medicines had 378 employees as of December 31, 2023. The number of employees increased by 132 or 53.66% compared to the previous year.
Employees
378
Change (1Y)
132
Growth (1Y)
53.66%
Revenue / Employee
$1,963
Profits / Employee
-$1,500,161
Market Cap
9.27B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 378 | 132 | 53.66% |
Dec 31, 2022 | 246 | 58 | 30.85% |
Dec 31, 2021 | 188 | 63 | 50.40% |
Dec 31, 2020 | 125 | 30 | 31.58% |
Dec 31, 2019 | 95 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Encompass Health | 37,761 |
Charles River Laboratories International | 21,800 |
Bio-Rad Laboratories | 8,030 |
Exact Sciences | 6,600 |
Qiagen | 5,967 |
Medpace Holdings | 5,900 |
Penumbra | 4,200 |
Sarepta Therapeutics | 1,314 |
RVMD News
- 11 days ago - Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 12 days ago - Revolution Medicines to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 - GlobeNewsWire
- 24 days ago - Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 26 days ago - Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 27 days ago - Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewsWire
- 5 weeks ago - Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast - GlobeNewsWire